Should minimal residual disease monitoring be the standard of care for all patients with acute promyelocytic leukemia?
Grimwade
David
D
Tallman
Martin S
MS
D000970:Antineoplastic Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D008991:Monitoring, Physiologic / Q000379:methods*; D018365:Neoplasm, Residual
D000970:Antineoplastic Agents